[Tolerance induction in anaphylaxis to carboplatin].
Herzinger
Th
T
Klinik und Poliklinik für Dermatologie und Allergologie, Klinikum der Universität München, Munich. Thomas.Herzinger@lrz.uni-muechen.de
Behr
J
J
Przybilla
B
B
D000008:Abdominal Neoplasms / Q000188:drug therapy / Q000556:secondary; D000368:Aged; D000707:Anaphylaxis / Q000139:chemically induced*; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D016190:Carboplatin / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D002927:Cimetidine / Q000008:administration & dosage*; D002974:Clemastine / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D003888:Desensitization, Immunologic / Q000379:methods*; D003907:Dexamethasone / Q000008:administration & dosage*; D004342:Drug Hypersensitivity / Q000517:prevention & control*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007211:Indoles / Q000008:administration & dosage*; D007262:Infusions, Intravenous; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011292:Premedication; D000077526:Tropisetron
D000970:Antineoplastic Agents; D007211:Indoles; D000077526:Tropisetron; D003907:Dexamethasone; D002927:Cimetidine; D002974:Clemastine; D016190:Carboplatin